Simponi and Tremfya: A Winning Combo for Ulcerative Colitis Remission

by telrheum | May 25, 2024 | Biologic Therapy, Colitis, IL-23 Inhibitors, Interleukin Inhibitors, tumour necrosis factor inhibitors (TNFis)

Background Ulcerative colitis is a chronic inflammatory condition affecting the colon. A recent study investigated the effectiveness of combining two drugs, Simponi, which blocks tumor necrosis factor-alpha, and Tremfya, which inhibits interleukin-23. This combination...

Revolutionizing Inflammatory Spine Care: The Power of Anti-IL-17 Drugs

by telrheum | May 25, 2024 | Spondyloarthritis, Biologic Therapy

Anti-IL-17 Drugs: A Guide Interleukin-17 (IL-17) is a protein that plays a crucial role in the body’s immune response. While it’s important for fighting infections, too much IL-17 can lead to inflammation and various autoimmune diseases, such as psoriasis, psoriatic...

Safeguarding Against Pneumocystis: Efficacy of TMP/SMX in Autoimmune Disease Management

by telrheum | May 19, 2024 | Autoimmune Diseases, Biologic Therapy, Pneumocystis Jirovecii

This systematic review and meta-analysis led by Athanasios Vassilopoulos and colleagues focuses on the effectiveness of prophylactic Trimethoprim-Sulfamethoxazole (TMP/SMX) in preventing Pneumocystis Jirovecii Pneumonia (PJP) among patients with Autoimmune...

Hepatitis B Reactivation with Rheumatoid Arthritis Treatment Choices

by telrheum | May 19, 2024 | Il-6 inhibitors, Hepatitis B, Infections, JAK Inhibitor

This study, presented at ACR Convergence 2023 by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, examines the risk of Hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) who are being treated with either JAK inhibitors or...

Rituximab-Induced Immunoglobulin Deficiency: A Closer Look at Infection Outcomes

by telrheum | May 19, 2024 | Biologic Therapy, Infections, Lupus, Rheumatoid Arthritis, Rituximab, Vasculitis

The article “Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases” by Claire Rempenault and colleagues evaluates the connection between severe infections and immunoglobulin deficiency in...

Balancing Treatment and Risk: HBV Reactivation in RA Patients on JAK and IL-6 Inhibitors

by telrheum | Apr 23, 2024 | Biologic Therapy, Il-6 inhibitors, Infections, JAK Inhibitor

This article, “Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis” by Akhil Sood, Janice Lin, and Neha Shah from Stanford University, presents a study that looks...